Stockreport

Jasper Therapeutics to Host an Investor Webinar on December 2nd to Present Preliminary Data from ETESIAN Study in Asthma and Findings from BEACON Study Investigation

Jasper Therapeutics, Inc. - Class A  (JSPR) 
PDF REDWOOD CITY, Calif., Dec. 01, 2025 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR) (Jasper or the Company), a clinical stage biotechnology company focuse [Read more]